- Project 1 - CaSR-mediated signalling in colonocytes
- Project 2 - Evaluation of CaSR - based therapeutics in prevention of tumourigenesis and metastatic potential in colorectal cancer
- Project 3 - Role of the CaSR in inflammatory lung diseases
- Project 4 - Evaluation of CaSR-targeted drugs for the treatment of neuroblastoma
- Project 5 - Delineation of CaSR signalling in primary cells and cell lines with native receptor expression
- Project 6 - Role of the calcium-sensing receptor (CaSR) in glucose homeostasis
- Project 7 - Cell-specific CaSR signaling
- Project 8 - Targeting CaSR in human skeletal muscle cells to delay sarcopenia development
- Project 9 - Evaluation of CaSR-targeted drugs for the treatment of diabetes mellitus
- Project 10 - Role of the CaSR in early bone metastasis of breast cancer cells and evaluation of CaSR - based therapeutics in prevention or delay of metastasis formation
- Project 11 - Ligand-biased G-protein activation by CaSR
- Project 12 - The role of CaSR in AD pathomechanisms
- Project 13 - In silico analysis of CaSR-ligand interaction
- Project 14 -Generation, validation and application of algorithms for tissue segmentation used in advanced tissue cytometry
Project 2 - Evaluation of CaSR - based therapeutics in prevention of tumourigenesis and metastatic potential in colorectal cancer
Host Institution: Medical University of Vienna
» Info
Hypothesis: Colorectal tumours expressing the CaSR are less aggressive, form fewer metastases, and are more susceptible to treatment and to the chemopreventive effect of Ca2+.
Objectives: ESRMUW2 will 1) test several substances such as epigenetic modifiers (DNA methyltransferase inhibitors and/or histone deacetylase inhibitors) and allosteric modulators of the CaSR are able to restore CaSR expression in vitro; 2) He will analyse potential synergies between DNMTi/HDACi and calcimimetics, regarding the expression of the CaSR and antitumourigenic properties. 3) and validate this in a colon cancer model in vivo; 4) ESRMUW2 will test the effect of CaSR-targeting drugs in AOM/DSS induced tumours in a model lacking the CaSR in the intestine. 5) In case of promising outcome, ESRMUW2 will test the effect of CaSR-targeting drugs on xenografts obtained from primary human colon tumours.
Quick Links
Featured
